# Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

> **NCT06178588** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Locally Advanced Cholangiocarcinoma
- Metastatic Cholangiocarcinoma
- Recurrent Cholangiocarcinoma
- Stage III Hilar Cholangiocarcinoma AJCC v8
- Stage III Intrahepatic Cholangiocarcinoma AJCC v8
- Stage IV Hilar Cholangiocarcinoma AJCC v8
- Stage IV Intrahepatic Cholangiocarcinoma AJCC v8

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **BIOLOGICAL:** Sacituzumab Govitecan

## Key facts

- **NCT ID:** NCT06178588
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-03-01
- **Final completion:** 2026-11-01
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06178588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06178588, "Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06178588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*